国际肿瘤学杂志最新文献

{"title":"Effect of perception control and self-management on cancer-related fatigue in breast cancer patients with chemotherapy","authors":"Ranran Li, Fuguo Yang, M. Fan, Wei Huang, Fang Yuan","doi":"10.3760/CMA.J.ISSN.1673-422X.2020.01.003","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2020.01.003","url":null,"abstract":"Objective \u0000To understand the status quo of perception control, self-management and cancer-related fatigue (CRF) in breast cancer patients receiving chemotherapy, and to investigate the impacts of perception control and self-management on CRF. \u0000 \u0000 \u0000Methods \u0000In this study, 246 breast cancer patients undergoing chemotherapy from Shandong Cancer Hospital and Institute were investigated by means of cross-sectional survey. Cancer experience and efficiency scale was used to evaluate the patients′ perception control; cancer patients′ self-management scale was used to assess their self-management; and Piper Fatigue Scale was used to evaluate their CRF. Finally, the scores of CRF among the patients with different demographic data were compared, and the effects of perception control and self-management behavior on CRF were analyzed. \u0000 \u0000 \u0000Results \u0000In univariate analysis, there were statistically significant differences of CRF scores resulting from different educational backgrounds (F=3.392, P=0.019), sources of medical cost (F=4.368, P=0.005), disease stages (F=4.376, P=0.005), chemotherapy periods (F=3.865, P=0.010) and courses of disease (F=3.094, P=0.028). The differences in each dimension of perceived control cancer experience (F=7.248, P=0.001), control efficacy (F=96.595, P<0.001), self-management level of cancer patients (F=65.009, P<0.001) and CRF (F=130.973, P<0.001) were statistically significant. Cancer experience in perception control was positively correlated with CRF (r=0.467, P<0.001); control effectiveness and self-management of cancer patients were negatively correlated with CRF (r=-0.505, P<0.001; r=-0.564, P<0.001). Multiple linear regression showed that source of medical expenses (setting commercial insurance as the reference group), chemotherapy cycle (setting chemotherapy cycle ≥ 6 cycles as the reference group), cancer experience, control effectiveness, and self-management were entered in regression models, which could explain 55.5% of the total variation in CRF scores, and there was a significant linear relationship (F=17.100, P<0.001). \u0000 \u0000 \u0000Conclusion \u0000Medical staff should focus on CRF in patients at their own expense and in the 2-5 chemotherapy cycles. Cancer experience is positively correlated with CRF. Control effectiveness and self-management behavior are negatively correlated with CRF. \u0000 \u0000 \u0000Key words: \u0000Breast neoplasms; Fatigue; Analysis of influence factor; Perception control","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"51 1","pages":"18-23"},"PeriodicalIF":0.0,"publicationDate":"2020-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74938295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preventive and therapeutic effects of common plant drugs on colon cancer and its mechanism","authors":"Huiping Zhou, Yuhua Li, Yuhui Wang, Y. Su, Yingying Yang, Xiaotian Xu, Xiaoqun Duan","doi":"10.3760/CMA.J.ISSN.1673-422X.2020.01.010","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2020.01.010","url":null,"abstract":"It is shown that phytochemicals have a protective effect on colon cancer. Curcumin, polysaccharides (apple polysaccharides, mushroom glucans), saponins (paridis saponins, ginsenosides), resveratrol, quercetin and other plant drugs can inhibit colon cancer cell proliferation and promote cell apoptosis through different signaling pathways. In addition, it also has anti-inflammatory, antioxidant, anti-angiogenesis, reduce the toxic side effects of chemotherapy drugs, and reverse the drug resistance of tumor cells. Understan-ding the prevention and cure effect of plant medicine on colon cancer and its possible mechanism can provide more theoretical basis and therapeutic ideas for the clinical prevention and cure of colon cancer. \u0000 \u0000Key words: \u0000Herbal drugs; Colonic neoplasms; Pharmacological action; Molecular mechanisms","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"2013 1","pages":"51-55"},"PeriodicalIF":0.0,"publicationDate":"2020-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86481068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mechanism study of PD-1/PD-L1 in tumor and its value of diagnosis and treatment of thyroid cancer","authors":"Lizhuo Zhang, Yangyang Qian, Guowan Zheng, M. Ge","doi":"10.3760/CMA.J.ISSN.1673-422X.2020.01.007","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2020.01.007","url":null,"abstract":"Programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) are involved in the regulation of immune checkpoints and are closely related to the occurrence and development of tumors. In thyroid cancer, an increase in PD-L1 expression and an increase in PD-1 positive T cells may be predictive of higher invasiveness and a greater risk of recurrence. Anti-PD-1/PD-L1 therapy has had significant effects in many tumors, but the efficacy in thyroid cancer is still relatively limited, which also requires finding biomarkers those can better predict the efficacy. Further understanding of the mechanism of PD-1/PD-L1, the current research status in thyroid cancer, and biomarkers related to its efficacy may provide new treatment methods and ideas for patients with thyroid cancer. \u0000 \u0000Key words: \u0000Thyroid neoplasms; Immunotherapy; PD-1/PD-L1","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"25 1","pages":"39-42"},"PeriodicalIF":0.0,"publicationDate":"2020-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87159651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of lncRNA MEG3 as ceRNA of miR-21 in cancer","authors":"Xing Li, Junxing Huang","doi":"10.3760/CMA.J.ISSN.1673-422X.2020.01.006","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2020.01.006","url":null,"abstract":"Long non-coding RNA (lncRNA)-maternally expressed gene 3 (MEG3) and microRNA-21 (miR-21) have been widely recognized as tumor suppressor and promoter. The competing endogenous RNA (ceRNA) hypothesis provides a new strategy for studying the interaction of RNAs. In recent years, studies have shown that MEG3 can play an important role in the occurrence, development, proliferation, metastasis, drug resistance and prognosis of breast cancer, cervical cancer, gastric cancer, lung cancer, leukemia and other malignant tumors as the ceRNA of miR-21. \u0000 \u0000Key words: \u0000Neoplasms; RNA, long noncoding; Competing endogenous RNA; Maternally expressed gene 3","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"199 1","pages":"35-38"},"PeriodicalIF":0.0,"publicationDate":"2020-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78488776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CCR6 promotes liver metastasis of colorectal cancer through epithelial-mesenchymal transition","authors":"Hailing Zhang, Juanfang Li, Xiaoqing Li, Linjie Shi, Yuan-fei Li","doi":"10.3760/CMA.J.ISSN.1673-422X.2020.01.005","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2020.01.005","url":null,"abstract":"Objective \u0000To detect the expressions of chemokine receptor 6 (CCR6), CC chemokine ligand 20 (CCL20) E-cadherin and vimentin in tissues of colorectal cancer and their paired liver metastases, and to investigate the possible mechanism of CCR6 in liver metastasis of colorectal cancer. \u0000 \u0000 \u0000Methods \u0000A total of 62 cases (54 cases of colon cancer and 8 cases of rectal cancer) of primary colorectal adenocarcinoma resection with wax lumps were selected from the First Hospital of Shanxi Medical University and Shanxi Oncology Hospital from 2009 to 2017 with complete data, including 20 samples of colorectal cancer resection with liver metastasis during the same period. The expressions of CCR6, CCL20, E-cadherin and vimentin in colorectal cancer and liver metastases tissues were detected by immunohistochemistry, and the relationships between the expressions of CCR6, E-cadherin and vimentin and the clinicopathological features of patients were analyzed. Logistic multivariate regression was used to analyze the relationship between liver metastasis and clinicopathological features, CCR6, E-cadherin and vimentin. Spearman correlation was used to analyze the correlations between CCR6 and E-cadherin and vimentin. \u0000 \u0000 \u0000Results \u0000The positive expression rate of CCR6 in colorectal cancer tissues was 66.1% (41/62), 85.0% (17/20) in colorectal cancer with liver metastasis and 70.0% (14/20) in liver metastasis tissues. The positive expression rate of CCL20 in colorectal cancer tissues was 83.9% (52/62), 90.0% (18/20) in colorectal cancer with liver metastasis and 90.0% (18/20) in liver metastasis tissues. The positive expression rate of E-cadherin in colorectal cancer tissues was 67.7% (42/62), 50.0% (10/20) in colorectal cancer with liver metastasis and 65.0% (13/20) in liver metastasis tissues. The positive expression rate of vimentin in colorectal cancer tissues was 79.0% (49/62), 85.0% (17/20) in colorectal cancer with liver metastasis and 90.0% (18/20) in liver metastasis tissues. The expression of CCR6 was closely related to lymph node metastasis (χ2=11.142, P=0.001), liver metastasis (χ2=4.694, P=0.030) and TNM stage (χ2=21.785, P 0.05). Logistic regression analysis showed that the expressions of CCR6 (OR=6.812, 95%CI: 1.206-38.474, P=0.030) and E-cadherin (OR=0.256, 95%CI: 0.069-0.945, P=0.041) were independent factors affecting the liver metastasis of colorectal cancer. Spearman correlation analysis showed that CCR6 was associated with E-cadherin expression (r=0.454, P=0.044) and vimentin expression (r=0.509, P=0.022) in 20 iver metastasis tissues of colorectal cancer. \u0000 \u0000 \u0000Conclusion \u0000CCR6 may promote colorectal cancer progress and liver metastasis by part of epithelial-mesenchymal transition. \u0000 \u0000 \u0000Key words: \u0000Colorectal neoplasms; Receptors, CCR6; Cadherins; Vimentin; Liver metastasis","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"72 1","pages":"29-34"},"PeriodicalIF":0.0,"publicationDate":"2020-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82020358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nilotinib in first-line treatment of chronic myeloid leukemia","authors":"L. Hong, Y. Wang, Qi Zhang, C. Lyu","doi":"10.3760/CMA.J.ISSN.1673-422X.2020.01.011","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2020.01.011","url":null,"abstract":"Chronic myeloid leukemia (CML) is a myeloproliferative tumor whose pathogenesis is related to the BCR/ABL fusion gene. Tyrosine kinase inhibitors (TKIs) can significantly improve the survival and prognosis of CML patients. Nilotinib is effective in first-line treatment of CML patients with rapid response, deep remission and high safety. After achieving a sustained deep molecular response, it is a new therapeutic goal for CML to stop the use of nilotinib and achieve treatment-free remission. In addition, due to disease resistance and mutations, how to start new treatments after nilotinib treatment failure is worth further research. \u0000 \u0000Key words: \u0000Leukemia, myeloid, chronic-phase; Tyrosine kinase inhibitor; Nilotinib","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"58 1","pages":"56-59"},"PeriodicalIF":0.0,"publicationDate":"2020-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73652995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"血清PGI、PGII、PGR、G-17水平与Hp-IgG联合检测对胃癌早期诊断的临床价值分析","authors":"袁培杰","doi":"10.3760/CMA.J.ISSN.1673-422X.2020.01.004","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2020.01.004","url":null,"abstract":"Objective \u0000To investigate the clinical value of combined detection of serum pepsinogen (PG)Ⅰ, PGⅡ, PGⅠ/PGⅡ (PGR), gastrin-17 (G-17) and IgG anti-Helicobacter Pylori (IgG anti-Hp) in the diagnosis of early gastric cancer. \u0000 \u0000 \u0000Methods \u0000One hundred and twenty patients with gastric cancer (early gastric cancer group), 60 patients with atrophic gastritis (atrophic gastritis group) and 120 healthy volunteers (control group) who were examined or treated in our hospital from January 2018 to June 2019 were selected as the subjects. The levels of serum PGⅠ, PGⅡ, PGR, G-17 and IgG anti-Hp were compared among the three groups. The indicators and combined diagnostic value were analyzed by receiver operating characteristic (ROC) curve. \u0000 \u0000 \u0000Results \u0000The levels of PGⅠ in early gastric cancer group, atrophic gastritis group and control group were (59.85±8.59)ng/ml, (72.19±9.89)ng/ml, (96.83±8.66)ng/ml, with statistically significant difference (F=530.504, P<0.001). The levels of PGⅡ in the three groups were (23.19±2.45)ng/ml, (20.60±4.19)ng/ml, (16.52±3.34)ng/ml, with statistically significant difference (F=130.085, P<0.001). The levels of PGR in three groups were 2.78±0.69, 4.33±0.95, 6.21±1.46, with statistically significant difference (F=288.801, P<0.001). The levels of G-17 in the three groups were (77.04±10.09)ng/ml, (64.69±7.22)ng/ml, (55.91±8.32)ng/ml, with statistically significant difference (F=170.770, P<0.001). The levels of IgG anti-Hp in the three groups were (70.23±8.11)IU, (58.30±9.37)IU, (33.00±5.24)IU, with statistically significant difference (F=778.431, P<0.001). The levels of serum PGⅠand PGR in early gastric cancer group and atrophic gastritis group were significantly lower than those in control group (all P<0.05). The levels of serum PGⅠand PGR in early gastric cancer group were significantly lower than those in atrophic gastritis group (both P<0.05). While serum PGⅡ, G-17 and IgG anti-Hp in early gastric cancer group and atrophic gastritis group were significantly higher than those in control group (all P<0.05). The levels of PGⅡ, G-17 and IgG anti-Hp in gastric cancer group were significantly higher than those in atrophic gastritis group (all P<0.05). According to the ROC curve, the critical value of serum PGⅠ diagnosis was 73.11 ng/ml, the sensitivity was 63.33%, the specificity was 83.33%, and the area under the curve (AUC) was 0.801. The critical value of serum PGⅡ diagnosis was 19.55 ng/ml, the sensitivity was 75.83%, the specificity was 72.22%, and the AUC was 0.760. The critical value of serum PGR diagnosis was 4.60, the sensitivity was 82.50%, the specificity was 77.22%, and the AUC was 0.816. The critical value of serum G-17 diagnosis was 64.33 ng/ml, the sensitivity was 64.17%, the specificity was 65.56%, and the AUC was 0.631. The critical value of IgG anti-Hp diagnosis was 53.80 IU, the sensitivity was 59.17%, the specificity was 75.00%, and the AUC was 0.708. At the critical tangent point, the sensitivity, specificity and AUC","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"10 1","pages":"24-28"},"PeriodicalIF":0.0,"publicationDate":"2020-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86234956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival analysis of postmastectomy radiotherapy for breast cancer staged in cT1-2N1M0 after neoadjuvant chemotherapy with 0-3 metastatic lymph nodes","authors":"Liyun Sun, Y. Lu, Shunkang Zhang, Gang Chen","doi":"10.3760/CMA.J.ISSN.1673-422X.2020.01.002","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2020.01.002","url":null,"abstract":"Objective \u0000To investigate the value of postoperative radiotherapy in patients with cT1-2N1M0 breast cancer after neoadjuvant chemotherapy and modified radical mastectomy which postoperative pathology showed that the number of axillary lymph node metastases was 0-3. \u0000 \u0000 \u0000Methods \u0000One hundred and twenty-eight patients diagnosed with cT1-2N1M0 breast cancer admitted to our hospital from January 1, 2000 to December 31, 2014 were retrospectively reviewed. All patients underwent neoadjuvant chemotherapy and modified radical mastectomy. The number of postoperative axillary lymph node metastases was 0-3. According to whether there was postoperative radiotherapy or not, the whole group of patients was divided into radiotherapy group (n=87) and non-radiotherapy group (n=41). In the two groups after operation, there were 43 and 11 patients with 1-3 axillary lymph node metastases (ypN1), while there were 44 and 30 patients without axillary lymph node metastases (ypN0) respectively. The 5-year locoregional recurrence-free survival (LRFS) rate, disease-free survival (DFS) rate and overall survival (OS) rate were calculated by Kaplan-Meier method, and the differences were compared by log-rank test. Univariate analysis was performed to analyze the effects of clinical features and treatment on prognosis. \u0000 \u0000 \u0000Results \u0000The 5-year LRFS rate, DFS rate and OS rate of 128 patients were 91.4%, 82.8% and 93.0% respectively. The 5-year LRFS rates of the patients in the radiotherapy group and the non-radiotherapy group were 94.3% and 85.4% respectively, and the difference was not statistically significant (χ2=3.055, P=0.080). As well as the 5-year DFS rates were 89.7% and 68.3% respectively, and the difference was statistically significant (χ2=9.312, P=0.005). The 5-year OS rates were 94.3% and 90.2% respectively, and the difference was not statistically significant (χ2=0.810, P=0.368). In the subgroup analysis, the 5-year LRFS rates of the patients who had achieved ypN1 in the radiotherapy group and the non-radiotherapy group were 93.0% and 72.7%, and the 5-year DFS rates were 88.4% and 63.6%, with statistically significant differences (χ2=4.248, P=0.039; χ2=4.525, P=0.033). The 5-year OS rates were 90.7% and 81.8% respectively, and the difference was not statistically significant (χ2=0.713, P=0.399). The 5-year LRFS rates of the patients who had achieved ypN0 in the radiotherapy group and the non-radiotherapy group were 95.5% and 90.0% respectively, with no statistically significant difference (χ2=0.872, P=0.350). The 5-year DFS rates were 90.9% and 70.0% respectively, with statistically significant difference (χ2=5.439, P=0.019). The 5-year OS rates were 97.7% and 93.3% respectively, with no statistically significant difference (χ2=0.876, P=0.349). The univariate analysis indicated that age (χ2=11.709, P=0.001) and blood vessel invasion (χ2=7.608, P=0.006) were significant influencing factors for 5-year LRFS rate. Postoperative radiotherapy (χ2=9.312, P=0.002) was a pr","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"35 1","pages":"10-17"},"PeriodicalIF":0.0,"publicationDate":"2020-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90542446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application and new progress of enhanced recovery after surgery in perioperative period of gastric cancer patients","authors":"Xin Xu, Bo Chen","doi":"10.3760/CMA.J.ISSN.1673-422X.2020.01.008","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2020.01.008","url":null,"abstract":"Enhanced recovery after surgery (ERAS) has been proved to be safe and effective in several surgical fields, including gastric cancer, and has been widely applied in clinical practice, covering preoperative, intraoperative and postoperative applications. However, there are still controversies regarding the implementation of ERAS in specific populations of gastric cancer and some specific implementation strategies. At the same time, the clinical application of ERAS also faces many problems. In the future, more high-quality evidence and professional clinical practice teams will be needed to promote the development of ERAS in the gastric cancer field. \u0000 \u0000Key words: \u0000Stomach neoplasms; Perioperative period; Enhanced recovery after surgery","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"2 1","pages":"43-45"},"PeriodicalIF":0.0,"publicationDate":"2020-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80796336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microbiota and pancreatic cancer","authors":"Z. Ji, De He","doi":"10.3760/CMA.J.ISSN.1673-422X.2020.01.009","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2020.01.009","url":null,"abstract":"In recent years, driven by high-throughput sequencing technology, it has been found that changes in the proportion of specific microbiota are related to the occurrence and development of pancreatic cancer, including oral microbes, gastrointestinal flora, and pancreatic flora. Porphyromonas has a positive correlation with pancreatic cancer risk, which may provide new biomarkers for the diagnosis of pancreatic cancer. In addition, the microbiota is closely related to various treatments for pancreatic cancer. When the intestinal flora is imbalanced, it will affect the effect of chemotherapy. Bacteria in pancreatic cancer can induce immune tolerance. Complications with bacterial infection can lead to postoperative complications increase. \u0000 \u0000Key words: \u0000Microbiota; Pancreatic neoplasms; Therapy","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"2003 1","pages":"46-50"},"PeriodicalIF":0.0,"publicationDate":"2020-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83015235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}